Cite
HARVARD Citation
Halota, W. et al. (2015). Oral anti‐CD3 immunotherapy for HCV‐nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase‐2a placebo‐controlled trial. Journal of viral hepatitis. 22 (8), pp. 651-657. [Online].